# Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

> **NCT05870007** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Taipei Medical University Shuang Ho Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Atorvastatin 20 Mg Oral Tablet
- **DRUG:** Sodium Bicarbonate 600 Mg Oral Tablet

## Key facts

- **NCT ID:** NCT05870007
- **Lead sponsor:** Taipei Medical University Shuang Ho Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-05
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870007, "Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05870007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*